JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

166.35 1.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

160.93

Máximo

167.26

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+20.42% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

508M

8.4B

Abertura anterior

164.7

Fecho anterior

166.35

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 23:08 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 23:07 UTC

Ganhos

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:20 UTC

Ganhos

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 de abr. de 2026, 23:27 UTC

Conversa de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 de abr. de 2026, 23:22 UTC

Ganhos

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 de abr. de 2026, 23:20 UTC

Conversa de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 de abr. de 2026, 22:52 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:33 UTC

Ganhos

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 de abr. de 2026, 22:05 UTC

Ganhos

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 21:57 UTC

Ganhos

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 de abr. de 2026, 21:55 UTC

Ganhos

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 de abr. de 2026, 21:53 UTC

Ganhos

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

20.42% parte superior

Previsão para 12 meses

Média 197.3 USD  20.42%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat